Market capitalization | $66.99m |
Enterprise Value | $-990.00k |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.01 |
P/B ratio (TTM) P/B ratio | 0.33 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-72.95m |
Free cash flow (TTM) Free cash flow | $-73.96m |
Cash position | $153.79m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
3 Analysts have issued a Instil Bio Inc forecast:
3 Analysts have issued a Instil Bio Inc forecast:
Mar '24 |
+/-
%
|
||
Net profit | -24 -24 |
57%
57%
|
|
Depreciation and amortization | 0.99 0.99 |
52%
52%
|
|
Share compensation | 4.52 4.52 |
0%
0%
|
|
Operating cash flow | -14 -14 |
58%
58%
|
|
Investments | - - |
-
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -14 -14 |
66%
66%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
Head office | United States |
CEO | Bronson Crouch |
Employees | 49 |
Founded | 2018 |
Website | www.instilbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.